Testing effectiveness (Phase 2)Active Not RecruitingNCT05690503
What this trial is testing
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Who this might be right for
Post-acute Sequelae of COVID-19Depressive SymptomsCognitive Dysfunction
New York State Psychiatric Institute 12